Skåne University Hospital
Malmö, 20502, Sweden
NCT Number: NCT05726097
The study aims to investigate the effect of the optimized bowel preparation and boost regimens on colon capsule endoscopy procedures, specifically on cleanliness and completion rate.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Malmö, 20502, Sweden
Colon capsule endoscopy (CCE) is a promising modality for lower gastrointestinal (GI) investigations in clinical routine and screening. Furthermore, the double-headed camera capsules are being applied for panenteric investigations, with promising results. The major limitation to its use has been finding a bowel preparation that will clean the colon adequately for good visualization of the mucosa and help propel the capsule using boosters through the colon. To achieve wider CCE adoption, challenges regarding completion rates (CR) and adequate cleanliness rates (ACR) must be handled. CR and ACR should be improved to meet the standards for optical colonoscopy (OC) from the European Society of GI Endoscopy (ESGE). ESGE recommends both CR and ACR ≥ 90%. Recently, a meta-analysis of preparation regimens for CCE confirmed that CR and ACR were suboptimal.
This study is designed to investigate the CR, ACR, and diagnostic yield (DY) of very low-volume polyethylene glycol (PEG) - based laxative compared to a conventional high-volume laxative and the use of different boosters.
All consecutive patients referred for colon capsule endoscopy will be enrolled in the study. PillCam® Crohn's capsule will be used. Patients will undergo a split-dose bowel preparation with a very low-volume PEG-based laxative. In the study arm nr1 gastrografin and magnesiumoxid + sodium picosulfate will be used. In the study arm Nr 2, the same regimen will be used but completed with 2 mg of prucalopride before ingesting the capsule. The results of the study arms will be compared to the previously used standard regimen with 4 L of PEG as a laxative and sodium phosphate as a booster.
The images from the colon capsule will be reviewed, and the quality of bowel preparation (cleanliness rates) and completion rate will be evaluated. Patient tolerance of the bowel preparations and diagnostic yield of colon capsule endoscopy using the different preparation regimens will also be evaluated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
colonic preparation
Other names: Laxabon
colonic preparation
Other names: Phosphoral
colonic preparation
Other names: Plenvu
colonic preparation
colonic preparation
Other names: Picoprep
colonic preparation
Other names: Resolol
Time frame: Within 3 months after completed capsule colonoscopy
Visualization of the hemorrhoidal plexus or an excreted capsule
Time frame: Within 3 months after completed capsule colonoscopy
Assessment of the quality of the bowel preparation using a the 4-point Leighton-Rex scale
Time frame: Within 3 months after completed capsule colonoscopy
Determining the amount of time for the capsule to transit through the stomach, small bowel and large bowel for the different preparations
Time frame: Within 3 months after completed capsule colonoscopy
Findings in the small and large bowel
Time frame: Within 3 months after completed capsule colonoscopy
Survey questionnaire to be completed by participants at the time of the colon capsule endoscopy assessing the tolerability of the preparation and side effects
Region Skane
Other
Optimization of the Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04369053
Adenoma, Colon Cancer
Birmingham, Alabama, United States
View Trial DetailsNCT05405530
Colon Cancer, Colon Polyp
Zhengzhou, Henan, China
View Trial DetailsNCT05030870
Colon Cancer, Colon Polyp
Zhenzhou, Henan, China
View Trial DetailsNCT06216405
Colon Adenocarcinoma, Colon Cancer
Paris, Île-de-France Region, France
View Trial Details